Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

WestGene Biopharma and Cartesian Therapeutics Forge $500M+ mRNA Partnership for In Vivo CAR-T and T Cell Engager Autoimmune Therapies

Fineline Cube Jun 10, 2026
Company Deals

Laekna Therapeutics Secures $527M Global Licensing Deal with Vasque Bio for PI3Kα Inhibitor LAE118, Retaining China Rights

Fineline Cube Jun 10, 2026
Company Deals

Everest Medicines Secures Asia-Pacific Rights to Vcare Pharma’s Next-Generation P2Y12 Inhibitor Sumecigrel in $3M Licensing Deal

Fineline Cube Jun 9, 2026
Company Deals Drug

Shandong Buchang Pharmaceuticals Partners with Vietnamese MKT for Exclusive Adalimumab Biosimilar Distribution in Vietnam

Fineline Cube Jun 9, 2026
Company Deals

Konruns Pharmaceutical to Acquire 30% Stake in Huamao Pharma for $28.2 Million, Achieving Vertical Integration from API to Finished Formulation

Fineline Cube Jun 9, 2026
Policy / Regulatory

China’s Four Health Regulators Issue Revised Good Clinical Practice Guidelines Effective September 2026, Strengthening Trial Oversight and Ethical Standards

Fineline Cube Jun 10, 2026
Company Drug

NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy

Fineline Cube Jun 10, 2026
Company Drug

Harbour BioMed’s TSLP Inhibitor HBM9378/WIN378 Doses First Patient in Phase II COPD Study with Windward Bio, Supporting Twice-Yearly Dosing Regimen

Fineline Cube Jun 10, 2026
Company

AstraZeneca Expands in China with Qingdao Partnership and Manufacturing Base

Fineline Cube Jun 21, 2022

UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is significantly expanding its presence in China through a...

Company Drug

CStone Pharmaceuticals’ Ayvakit Included in Taiwan’s National Health Insurance

Fineline Cube Jun 21, 2022

China-based CStone Pharmaceuticals (HKG: 2616) announced that its Ayvakit (avapritinib), a tyrosine kinase inhibitor for...

Company Deals

Eureka Biotechnology Secures RMB 100 Million for Cell and Gene Therapy Solutions

Fineline Cube Jun 21, 2022

Shenzhen-based Eureka Biotechnology, a company specializing in comprehensive solutions for the cell and gene therapy...

Company Deals

Therorna Secures Over RMB 280 Million in Series A Round to Accelerate circRNA Tech Development

Fineline Cube Jun 21, 2022

China-based Therorna Inc., a biotech company specializing in cutting-edge circular RNA (circRNA) technology for next-generation...

Company Medical Device

Qingdao HuaRen Pharmaceutical Gains CE Marks for Monkeypox and COVID-19 Detection Kits

Fineline Cube Jun 21, 2022

China-based Qingdao HuaRen Pharmaceutical Co., Ltd (SHE: 300110) has announced receiving CE marks in the...

Company Drug

SSY Group’s Blonanserin and Paracetamol Approved by China’s NMPA

Fineline Cube Jun 21, 2022

China-based SSY Group Limited (HKG: 2005) has announced receiving market approvals from the National Medical...

Company Deals

Shanghai ShineYo Medical Device Secures RMB 100 Million in Series A Round

Fineline Cube Jun 21, 2022

Shanghai ShineYo Medical Device Co., Ltd, a company specializing in electrophysiology and peripheral intervention, has...

Company Deals R&D

Boehringer Ingelheim Venture Fund and Hong Kong Science Park Launch Co-Incubation Plan

Fineline Cube Jun 20, 2022

Germany-based pharmaceutical giant Boehringer Ingelheim’s venture fund (BIVF) and China-based Hong Kong Science & Technology...

Company Drug

Innovent Biologics’ Tyvyt Approved for First-Line Esophageal Squamous Cell Carcinoma

Fineline Cube Jun 20, 2022

The National Medical Products Administration (NMPA) website indicates that China-based Innovent Biologics, Inc. (HKG: 1801)...

Policy / Regulatory

China’s Seventh National Volume-based Procurement Round Kicks Off with Revised Rules

Fineline Cube Jun 20, 2022

China’s health authorities have resumed the seventh national volume-based procurement (VBP) round after a pandemic-related...

Company Deals

Shenzhen AXBio Closes USD 100 Million Series B Round for Sequencing Tech Expansion

Fineline Cube Jun 20, 2022

Shenzhen-based fourth-generation sequencing company Anxuyuan Biotechnology (shenzhen) Company Limited (AXBio) has reportedly secured close to...

Company Medical Device

Boston Scientific Launches Expect Airway Ultrasound Needle in China for Lung Cancer Diagnosis

Fineline Cube Jun 20, 2022

US-based Boston Scientific Corporation (NYSE: BSX) has announced the official market launch of its Expect...

Company Deals

Iomics Biosciences Secures RMB 100 Million for Proteomics and Spatialomics Expansion

Fineline Cube Jun 20, 2022

Beijing-based Iomics Biosciences Co., Ltd, a developer of gene sequencing and diagnostic equipment, has reportedly...

Company Drug

InnoCare and Keymed Biosciences’ CCR8-Targeted mAb CM369 Accepted by NMPA

Fineline Cube Jun 20, 2022

China-based InnoCare (HKG: 9969) and Keymed Biosciences Inc. (HKG: 2162) announced that an Investigational New...

Policy / Regulatory

CDE Releases 58th and 59th Batches of Chemical Generic Reference Preparations

Fineline Cube Jun 20, 2022

The Center for Drug Evaluation (CDE) has released the 58th and 59th batches of chemical...

Company Deals

Shenzhen’s LWPOCT Secures RMB 100 Million in Series A Round for CDMO Expansion

Fineline Cube Jun 20, 2022

Shenzhen-based medical devices and reagents manufacturer Shenzhen Living Water POCT Co., LTd (LWPOCT) has reportedly...

Company Drug

Henlius Biotech Begins Global Phase III Trial for Denosumab Biosimilar HLX14

Fineline Cube Jun 20, 2022

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a...

Company Drug

Cellular Biomedicine Group’s C-CAR039 Receives NMPA Approval for B-Cell NHL Study

Fineline Cube Jun 20, 2022

China-based Cellular Biomedicine Group Inc. (CBMG), a private company following a merger deal in February...

Company Deals

Global Cord Blood Corp’s Cellenkos Gets FDA Nod for Myelofibrosis Trial

Fineline Cube Jun 20, 2022

Global Cord Blood Corporation (GCBC; NYSE: CO) announced receiving Investigational New Drug (IND) approval from...

Company Deals

Hangzhou Tongee Medical Closes RMB 100 Million Series B Round for Gastric Bypass Stent

Fineline Cube Jun 19, 2022

Hangzhou Tongee Medical Technology Co., Ltd, a Chinese device maker specializing in metabolic disease treatments,...

Posts pagination

1 … 675 676 677 … 681

Recent updates

  • NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy
  • Harbour BioMed’s TSLP Inhibitor HBM9378/WIN378 Doses First Patient in Phase II COPD Study with Windward Bio, Supporting Twice-Yearly Dosing Regimen
  • Haisco Pharmaceutical Files Nav1.8 Inhibitor HSK51155 with NMPA Following $700M+ AbbVie Licensing Deal for Novel Pain Therapeutic
  • Huadong Medicine’s Ellansé S Dermal Filler Receives NMPA Acceptance for Forehead Contouring Indication, Expanding China’s Premium Aesthetic Portfolio
  • Henlius Biotech’s Serplulimab Becomes World’s First PD-1 Inhibitor Approved for Perioperative Gastric Cancer Treatment Following Landmark Phase III Results
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy

Company Drug

Harbour BioMed’s TSLP Inhibitor HBM9378/WIN378 Doses First Patient in Phase II COPD Study with Windward Bio, Supporting Twice-Yearly Dosing Regimen

Company Drug

Haisco Pharmaceutical Files Nav1.8 Inhibitor HSK51155 with NMPA Following $700M+ AbbVie Licensing Deal for Novel Pain Therapeutic

Company Medical Device

Huadong Medicine’s Ellansé S Dermal Filler Receives NMPA Acceptance for Forehead Contouring Indication, Expanding China’s Premium Aesthetic Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.